Practical management of nocturia in urology

Myeong Heon Jin, Du Geon Moon
Department of Urology, Korea University College of Medicine, Seoul, Korea

ABSTRACT

Until last decades, nocturia has been considered as an irritative symptom of benign prostatic hyperplasia (BPH), but the nocturia is unresponsive symptoms to various modalities of BPH treatment. More recently, it has been recognized that the prostate is not so quite important as previously believed, as nocturia is equally common in women. The understanding of nocturia has been much changed in last decade; it is a highly prevalent condition, and symptoms in men and women are really no different either quantitatively or qualitatively. The successful introduction of desmopressin (l-deamino-8-D-arginine vasopressin, DDAVP) to decrease nocturnal urine output in severe nocturia which resistant to conventional BPH treatment and in women demonstrated new perspectives in management of nocturia. We reviewed the definition and etiologies of nocturia, offering the current diagnostic procedures and standards of care.

Key words: Nocturia, review, urology

DEFINITION

Recently, nocturia has only been recognized as a separate clinical entity within the lower urinary tract symptom complex. The pathophysiology of nocturia is multifactorial and can be complex and its cause remains unclear in a significant number of patients. The growing recognition that nocturia is a condition in its own right was reflected in the meeting ‘Nocturia - towards a consensus’ that was convened in Athens in 1998. The International Continence Society (ICS) defines nocturia as “the complaint that the individual has to wake at night one or more times to void.” The ICS and also defines nocturnal urine volume (NUV) as “the total volume of urine passed between the time the individual goes to bed with the intention of sleeping and the time of waking with the intention of rising.” Thus, NUV does not include the last void before going to bed, but it does include the first morning void. An important consideration of nocturia is whether the patient is awakened by the need to void, or if the patient voids after being awakened for some other reason. Every patient of nocturia does not need treatment. Patients who are awakened by nocturia and suffered from lack of sleep are candidates for evaluation. In clinical practice, most people do not seek treatment for 1-2 times of nocturia. So, severe nocturia >2-3 times per night will be evaluated. Sleep time varies by individual, but on average, it is 8 h per night. This can affect the evaluation of nocturia, because the number of nocturnal voids depends partly on how many hours an individual actually sleeps. Shift workers may have a variation in their nighttime, and the same definition exists for them. This is important, because more than 15 million of the general populations are shift workers who sleep during the day.

PREVALENCE

Early prevalence studies used varied definitions of what might constitute a problem, whereas later studies have conformed to the ICS definition and related nocturnal frequency to its associated impact. Although there are limited data on the frequency of voiding and volume voided nocturnally across all age groups, prevalence in community-dwelling populations has been measured and is typically present in >50% of both men and women aged >60 years. The prevalence increases with age such that the vast majority of any population of men and women of 80 years and over will rise at least once at night to empty their bladder. The descriptive epidemiological data on nocturia indicate that this symptom increases with age and the steepest increase is in older groups (>65 years). There were no large differences in the prevalence of nocturia between men and women; however, there is a tendency for young women to have this symptom more often than young men, and for very old men to have it more often than very old women. Typical ranges for ≥2 nocturia episodes/night are 5-15% for those aged 20-50 years, 20-30% for those aged 50-70 years, and 10-50% for those aged ≥70 years [Figure 1].

For correspondence: Dr. Du Geon Moon, Department of Urology, Korea University Guro Hospital, 80, Guro-dong, Guro-gu, Seoul 152-050, Korea.
E-mail: dgmoon@korea.ac.kr
IMPACT OF NOCTURIA

Nocturia is relatively common among the elderly and becomes increasingly prevalent with age, with profound influences on health and quality of life (QoL). Sleep fragmentation and disruption may result in daytime sleepiness, tiredness, mood changes, and cognitive dysfunction with poor concentration and performance.[9,10] More than 60% of men and women reported that nocturia had a negative effect on their QoL.[8] In fact, nocturia is often quoted as the most bothersome of lower urinary tract symptoms, and there is an association between the extent of impact and the frequency of nocturnal voiding.[11-14] A quarter of community-dwelling individuals aged 65-74 years and a third of those of aged ≥75 years experience one or more falls every year.[15] A quarter of the falls occur at night, and more than a quarter of these nocturnal falls occur in relation to toilet visits.[16]

Recently, the impact of nocturia on productivity at work, vitality and QoL were assessed among professionally active individuals in Sweden.[17] Over 200 individuals reporting, on average, more than two voids per night were compared with a group of age- and gender-matched controls without nocturia. This study clearly showed that lack of sleep caused by excessive nighttime voiding leads to lower energy levels (vitality), impaired work-related productivity, and reduced QoL compared with controls. Nocturia also has been known to be linked to a heightened risk for traffic accidents, morbidity, mortality, and significant health costs to both the patient and the physician.[18] Until recently, there was no condition-specific quality-of-life instrument which assessed the impact of nocturia upon well-being. The recently developed nocturia quality-of-life questionnaire measurement tool consists of 13 items assessing productivity, level of activity impairment, energy, fatigue, and worry. The score is able to discriminate between men experiencing one, two, or three or more episodes of nocturia. It has not yet been validated for use in women.[19]

DIFFERENTIAL DIAGNOSIS

Because the ICS definition of nocturia does not suggest causation, it is necessary to consider the reasons of nocturia in each individual. The underlying pathophysiologic process of nocturia comprises four main conditions: (i) global polyuria, (ii) nocturnal polyuria, or nocturnal urine overproduction, (iii) bladder storage problems, or decreased nocturnal bladder capacity (NBC), and (iv) mixed.

Global polyuria

Polyuria is continuous overproduction of urine not limited to sleep hours and defined as 24-h urine output of more than 40 ml/kg. Polyuria occurs in response to the increased fluid intake, which in turn leads to excessive urine production. As a result, polyuria is usually associated with increased urinary frequency during both daytime and nighttime. The common causes of global polyuria are diabetes mellitus, diabetes insipidus (DI), and primary thirst disorders. The less common form of diabetes, DI, is a disorder of water balance in the body. Inappropriate excretion of urine may lead to polydipsia to prevent circulatory collapse. Central DI is caused by deficient synthesis of antidiuretic hormone secondary to the loss of neurosecretory neurons in the hypothalamus or posterior hypophysis. In nephrogenic DI, the pituitary gland produces a normal amount of antidiuretic hormone, but the kidneys do not respond appropriately to it.[20] Diagnosis is made by overnight water deprivation to determine whether the urine becomes more concentrated. If the first morning void is not highly concentrated, DI is diagnosed. Central DI usually can be treated with desmopressin.[21] Nephrogenic DI may be treated with judicious regulation of fluid intake. If the water deprivation test is normal in a patient experiencing polyuria, the diagnosis is a primary thirst disorder such as polydipsia, which may be either dipsogenic or psychogenic. In polydipsia, the patient demonstrates normal renal concentrating capacity. Although not classified, polyuria could be observed in patients taking excessive fluid to maintain general health from medical misknowledge.

Nocturnal polyuria or nocturnal urine overproduction

Nocturnal polyuria is defined as an increase in nighttime urine production with a corresponding decrease in daytime urine production, resulting in a normal 24-h urine volume. Similar to the pathophysiology of nocturnal enuresis, a disruption in the diurnal secretion patterns of arginine vasopressin (AVP) has been proposed for nocturia.[22] In 2004, the authors studied the circadian variation of AVP and urine output in patients with severe nocturia.[23] Compared with the normal control, the nocturia patients had no diurnal variation in urine output and greater nocturnal urine production, associated with a lack of nocturnal increase in AVP level. Secondary causes of nocturnal polyuria include congestive heart failure; diabetes mellitus; peripheral edema due to venous stasis or lymphostasis, nephritic syndrome, hepatic failure, or hypoalbuminemia; or lifestyle patterns such as excessive nighttime drinking. In clinics, patients of
voided volume (MVV) or decreased NBC.

Decreased sleep. Decreased NBC can be related to decreased maximum volumes is indicative of nocturnal polyuria.

Patients with nocturia who do not have either polyuria or nocturnal polyuria according to the above criteria, will most likely have a reduced voided volume or a sleep disorder. NBC is defined as the largest voided volume during the hours of sleep. Decreased NBC can be related to decreased maximum voided volume (MVV) or decreased NBC.

Decreased NBC can be related to prostatic obstruction, nocturnal detrusor overactivity, neurogenic bladder, primary bladder pathology such as cancer (bladder, prostate, or urethra), learned voiding dysfunction, anxiety disorders, certain pharmacological agents, or bladder and ureteral calculi.

Some mathematical indices have been suggested to describe this situation.

NBC index (NBCi) is a more complicated formula that addresses voids at night in patients with decreased NBC. NBCi is actual number of nightly voids (ANV) minus predicted number of nightly voids (PNV) [Table 1]. PNV is derived by calculating nocturia index (Ni) (NUV/MVV) and subtracting 1. NBCi greater than 0 indicates nocturia occurring at volumes less than MVV.

**Mixed nocturia**

A significant number of nocturia cases are related to more than 1 etiology. Mixed nocturia is a combination of nocturnal polyuria and decreased NBC, and it is more common than many realize. In a study of 194 patients in whom nocturia was a chief or significant complaint, 7% were determined to have simple nocturnal polyuria, 57% had decreased NBC, and 36% had a mixed etiology, combining the first two etiologies.

Thus, nocturnal polyuria was a factor in nocturia in 43% of the patients evaluated. It was concluded that the etiology of nocturia was multifactorial and often unrelated to an underlying urological condition, such as prostatism. Mixed nocturia is diagnosed through the maintenance and analysis of bladder diaries. Through the formulas noted in Table 1, it is possible to assess the relative contribution of nocturnal polyuria and decreased NBC.

### CLINICAL ASSESSMENT OF NOCTURIA

As with any patient, a detailed history of the problem is required. It is essential to establish what is normal for the patient and whether there has been a change from normal. If there has been a change, either sudden or gradual then the amount by which the patient is bothered by the symptom should dictate whether further investigation of the problem is required. As in the management of all lower urinary tract symptoms, there should also be an assessment of the patient’s own desired objectives following treatment. This will allow a problem-based approach to management. An initial screen should include a detailed history, including questions relevant to voiding behavior, medical and neurological abnormalities, and sleep disturbance, as well as information on relevant surgery or previous urinary infections. A simple urine test, e.g. dipstick or urine analysis, should be undertaken to exclude any relevant pathology. The patient should also have a physical examination. During physical examination, patients should be screened for edema, age-related changes of the genitalia, and prolapse. Neurologic examination should include evaluation of anal sphincter tone, the bulbocavernous reflex, and sensation in the sacral dermatomes.

The assessment of nocturia can be described by a simple algorithm [Figure 2]. This considers the possibility that the patient may present to the physician specifically because of nocturia, or may present with another condition, while also having nocturia. The principal diagnostic tool for use in the assessment of nocturia is the voiding bladder diary. Based

### Table 1: Formulas for nocturia evaluation

| Formula | Analysis |
|---------|----------|
| Nocturia index<br>\( Ni = \frac{NUV}{MVV} \) | \( Ni > 1: \) nocturia is due to NUV exceeding MVV |
| Nocturnal polyuria index<br>\( NPi = \frac{NUV}{24 \text{ hV}} \) | \( NPi > 35\%: \) diagnosis is nocturnal polyuria |
| Nocturnal bladder capacity index<br>\( NBCi = ANV - PNV \) | \( NBCi > 0: \) nocturia occurring at volumes < MVV |

*Round up to next higher number if Ni - 1 is not an integer*

### Table 2: Causes of polyuria

| Category | Description |
|----------|-------------|
| Diabetes mellitus | Insulin dependent (Type I) Insulin independent (Type II) |
| Diabetes insipidus | Pituitary Renal Gestational |
| Primary polydipsia | (psychogenic, dipsogenic, or iatrogenic) |

Jin and Moon: Updates in the management of nocturia
on information about urinary frequency and volume that is recorded by the patient in the diary, a physician can classify the patient as having polyuria, nocturnal polyuria, or bladder storage problems. Information that should be collected and recorded in the voiding bladder diary includes timing of voids, number of voids, and volume of urine voided. Fluid intake volume and time of fluid intake should also be recorded. When collecting these data, patients include the first morning void in the NUV because the kidneys excreted this amount during sleep. However, the first morning void is considered a normal episode and is not included with the number of nightly voids.

**TREATMENT**

Lifestyle factors

Managing nocturia is best based on an approach that targets the underlying causes, but changes in several empirical lifestyle factors might be effective. Restriction of caffeine and alcohol intake may help some patients with nocturia. Fluid restriction before bedtime may help to alleviate the disorder, especially in patients who also have urgency incontinence. Griffiths et al. studied 128 incontinent elderly patients and found that evening fluid restriction reduced nocturnal urine excretion by a small amount in those with severe urgency incontinence. Some data suggest that this method alone may not be ideal for alleviating nocturia in the elderly. For instance, Asplund and Åberg found that nearly half of those who woke ≥3 times a night to urinate already restricted their fluid intake in the evening. In cases of nocturnal polyuria, the urine output cannot be reduced by restricting fluid intake, because of a lack of circulating AVP and an inability to respond with inhibition of the diuresis after fluid restriction. Also fluid restriction before bedtime is rarely effective if nocturia is the result of gravity-induced third spacing of fluid in the lower extremities. In this situation, fluid is mobilized when the patient assumes a recumbent position. Compression stockings, if worn by the patient during ambulatory periods, may prevent fluid accumulation in the legs, thus helping to diminish nocturnal urinary output. Diuretics given during the late afternoon or early evening may also help to decrease third spacing of fluid. If given later during the evening, however, diuretics may increase nocturia [Table 3].

**Surgery**

Transurethral prostatectomy/transurethral incision of the prostate may be appropriate when obstruction related to the prostate is believed to be a significant causative factor of nocturia. Surgical correction of pelvic organ prolapse, sacral nerve neuromodulation, detrusor myectomy, and clam cystoplasty are options for the treatment of patients with intractable nocturia associated with overactive bladder (OAB).

**Pharmacotherapy**

To date, desmopressin, a synthetic analog of AVP, is the only available antidiuretic drug, and has been used for over 30 years in the treatment of disorders such as DI and primary nocturnal enuresis (PNE). As it is now recognized that nocturnal polyuria is also a major component of nocturia, the place of desmopressin for treating nocturia is gaining acceptance. Several clinical trials investigating the benefits of desmopressin therapy for patients with nocturia have been completed. These randomized, double-blind, placebo controlled, NOCTUPUS trials assessed the short- and long-term efficacy, and safety of desmopressin in nocturia in men and in women treated with oral desmopressin at bedtime. In the short-term (3 weeks) trials, 33% of males and 46% of females desmopressin-treated patients showed a ≥50% reduction in the mean number of voids per night relative to baseline (P < 0.001 and P < 0.0001, respectively, compared with placebo). All other efficacy endpoints, including the mean number of nocturnal voids and the duration of the first sleep period until the first nocturnal void, showed a highly significant difference in favor of desmopressin compared with placebo. Quality of life analyses also indicated a greater improvement in terms of prevalence, bother, and problems caused by nocturia, in patients treated with desmopressin compared with placebo. Of patients completing the short-term NOCTUPUS studies, 88% entered the 10-12-month extension study. At 12 months, the proportion of patients with a ≥50% reduction in the number of nocturnal voids compared with baseline increased from 37 to 67% in males, and from 46 to 67% in females. Overall, efficacy in all

**Table 3: Causes of nocturnal polyuria**

| Causes of nocturnal polyuria |
|-----------------------------|
| Water diuresis               |
| Circadian defect in secretion or action of antidiuretic hormone |
| Primary (idiopathic)         |
| Secondary (excessive evening intake of fluid, caffeine, alcohol) |
| Solute/water diuresis        |
| Congestive heart failure     |
| Autonomic dysfunction        |
| Sleep apnoea syndrome        |
| Renal insufficiency          |
| Estrogen deficiency          |
Table 4: Causes of problems related to bladder storage

Reduced functional bladder capacity (e.g. significant postvoid residual)
Reduced nocturnal bladder capacity
Detrusor overactivity
Neurogenic (e.g. multiple sclerosis)
Nonneurogenic
Bladder hypersensitivity
Bladder outlet obstruction with postvoid residual urine
Urogenital ageing

Table 5: Sleep disorders potentially related to nocturia

Insomnia
Obstructive and central apnoea syndrome
Periodic legs syndrome
Restless legs syndrome
Parasomnias
Sleep disorders related to medical diseases, e.g. chronic obstructive lung disease, cardiac diseases, etc.
Sleep disorders related to neurological diseases, e.g. Alzheimer’s, Parkinson’s and nocturnal epileptic seizures

Patients with nocturia associated with detrusor overactivity, a component of overactive bladder syndrome and the common symptom of urgency incontinence,[37] may respond to drugs that affect bladder contractility. These drugs include the antimuscarinic agents oxybutynin and tolterodine, which can substantially reduce the voiding frequency in patients with overactive bladder. [38,39] Solifenacin and other new antimuscarinic drugs in development for treating overactive bladder, e.g. darifenacin, have potentially better safety and tolerability profiles than the older antimuscarinic agents. [40,41]

REFERENCES

1. van Kerrebroeck P, Abrams P, Chaikin D, Donovan J, Fonda D, Jackson S, et al. The standardisation of terminology in nocturia: Report from the standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:179-83.
2. Weiss JP, Blaivas JG, Stember DS, Brooks MM. Nocturia in adults: Etiology and classification. Neurourol Urodyn 1998;17:467-72.
3. Beers TM. Flexible schedules and shift work: Replacing the ‘9-to-5’ workday? Mon Labor Rev 2000;123:33.
4. Hennessy CH, Shen JKM. Sources of unreliability in the multidisciplinary assessment of the elderly. Eval Rev 1986;10:78.
5. Lundgren R. Nocturia: A new perspective on an old symptom. Scand J Urol Nephrol 2004;38:112-6.
6. Lose G, Alling-Moller L, Jensen P. Nocturia in women. Am J Obstet Gynecol 2001;185:514-21.
7. Jolleys JV, Donovan JL, Nanchahal K, Peters TJ, Abrams P. Urinary symptoms in the community: How bothersome are they? Br J Urol 1994;74:551-5.
8. Schatzl G, Temml C, Schmidbauer J, Dolezal B, Haidinger G, Madersbacher S. Cross-sectional study of nocturia in both sexes: Analysis of a voluntary health screening project. Urology 2000;56:71-7.
9. Mahowald ML, Mahowald MW. Nighttime sleep and daytime functioning (sleepiness and fatigue) in well-defined chronic rheumatic diseases. Sleep Med 2000;1:179-93.
10. Hetta J. The impact of sleep deprivation caused by nocturia. BJU Int 1999;84:27-8.
11. Miceli P. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int 2004;94:194-5.
12. Eckhardt MD, van Venrooij GE, Boon TA. Symptoms and quality of life versus age, prostate volume, and urodynamic parameters in 565 strictly selected men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2001;57:695-700.
13. Jensen J, Lundin-Olsson L, Nyberg L, Gustafson Y. Symptoms, bothersomeness and quality of life in patients with LUTS suggestive of BPH. Eur Urol 2001;40:13-8.
14. Bertaccini A, Vassallo F, Martino F, Zuzli S, Di Silverio F, et al. Symptoms, bothersomeness and quality of life in patients with nocturia. BJU Int 2003;91:190-5.
15. Jensen J, Lundin-Olsson L, Nyberg L, Gustafson Y. Falls among frail older people in residential care. Scand J Public Health 2002;30:54-61.
16. Kobelt G, Borgström F, Mattiasson A. Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU Int 2003;91:190-5.
17. Jennum P. Sleep and nocturia. BJU Int 2002;79:21-4.
18. Abraham L, Hareendran A, Mills IW, Martin ML, Abrams P, Drake MJ, et al. Development and validation of a quality-of-life measure for men with nocturia. Urology 2004;63:481-6.
19. Weiss JP, Blaivas JG. Nocturnal polyuria versus overactive bladder in nocturia. Urology 2002;60:28-32.
20. Rivkees SA, Dunbar N, Wilson TA. The management of central diabetes insipidus in infancy: Desmopressin, low renal solute load formula, thiazide diuretics. J Pediatr Endocrinol Metab 2007;20:459-69.
21. Moon DG, Jin MH, Lee JG, Kim JH, Lim MG, Cha DR. Anti-diuretic hormone in elderly male patients with severe nocturia: A circadian study. BJU Int 2004;94:571-5.
22. Matthiesen TB, Rittig S, Nørgaard JP, Pedersen EB, Djurhuus JC. Nocturnal polyuria and natriuresis in male patients with nocturia and lower urinary tract symptoms. J Urol 1996;155:1292-9.
23. Weiss JP, Blaivas JG. Nocturia. Curr Urol Rep 2003;4:362-6.
24. Weiss JP, Blaivas JG, Stember DS, Brooks MM. Nocturia in adults: Classification and etiology. Neurourol Urodyn 1998;17:467-72.
Indian Journal of Urology 294 | July-September 2008 

27. Griffiths DJ, McCracken PN, Harrison GM, Gormley EA. Relationship of fluid intake to voluntary micturition and urinary incontinence in geriatric patients. Neurourol Urodyn 1993;12:1-7.
28. Asplund R, Åberg H. Health of the elderly with regard to sleep and nocturnal micturition. Scand J Prim Health Care 1992;10:98-104.
29. Weiss JP, Blaivas JG. Nocturia. J Urol 2000;163:5-12.
30. Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J. Efficacy of desmopressin in the treatment of nocturia: A double-blind placebo-controlled study in men. BJU Int 2002;89:855-62.
31. Lose G, Lalos O, Freeman RM, van Kerrebroeck P; Nocturia Study Group. Efficacy of desmopressin (Minirin) in the treatment of nocturia: A double-blind placebo-controlled study in women. Am J Obstet Gynecol 2003;189:1106-13.
32. Van Kerrebroeck P, Rezapour M, Cortesse A, Thuroff J, Riis A, Norgaard JP. Desmopressin in the treatment of nocturia: A double-blind, placebo-controlled study. Eur Urol 2007;52:221-9.
33. Lose G, Mattiasson A, Walter S, Lalos O, van Kerrebroeck P, Abrams P, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol 2004;172:1021-5.
34. Weatherall M. The risk of hyponatraemia in older adults using desmopressin for nocturia: Systematic review and meta-analysis. Neurourol Urodyn 2004;23:302-5.
35. Rembratt A, Riis A, Norgaard JP. Desmopressin treatment in nocturia: An analysis of risk factors for hyponatremia. Neurourol Urodyn 2006;25:105-9.
36. Bae JH, Oh MM, Cheon J, Lee JG, Kim JJ, Moon DG, et al. The effects of long-term administration of oral desmopressin on the baseline secretion of antidiuretic hormone and serum sodium concentration for the treatment of nocturia: A circadian study. J Urol 2007;178:200-3.
37. Williams G, Donaldson R. A novel therapy for nocturnal polyuria: A double-blind randomized trial of frusemide against placebo. Br J Urol 1998;82:165-6.
38. Diokno AC, Appel RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: Results of the OPERA trial. Mayo Clin Proc 2003;78:687-95.
39. Homma Y, Paick JS, Lee JG, Kawabe K; for the Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: A randomized, placebo-controlled trial. BJU Int 2003;92:741-7.
40. Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, et al. for the YM-905 Study Group. Prospective, randomized, double-blind placebo-and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93:303-10.
41. Rovner ES, Wein AJ. Update on overactive bladder: Pharmacologic approaches on the horizon. Curr Urol Rep 2003;4:385-90.

How to cite this article: Jin MH, Moon DG. Practical management of nocturia in urology. Indian J Urol 2008;24:289-294.

Source of Support: Nil, Conflict of Interest: None declared.